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Directed differentiation of human embryonic stem cells (hESCs) may yield models to study organogenesis,
produce cells and tissues for therapies, and identify clinically relevant compounds for disease treatment. Op-
timal conditions for specific differentiation of hESCs are still being determined. Incorporation of fluorescent
reporter genes will enable high-throughput screening to identify fate-specifying molecules. Ectopic expres-
sion, or silencing, of key developmental genes can also direct differentiation toward specific lineages. Here,
we briefly overview various genetic modifications used to generate useful hESC lines. We identify strengths
and limitations to each method and propose the most suitable approaches for different applications.Introduction
Given that hESCs have the potential to produce unlimited quan-
tities of any human cell type (Reubinoff et al., 2000; Thomson
et al., 1998), considerable focus has been placed on their thera-
peutic potential. At present, the culture conditions required for
efficient hESC differentiation toward individual lineages remain
unknown, but progress is increasing rapidly (Hoffman and Car-
penter, 2005; Trounson, 2006). Efforts in this process have
been hampered by the challenges associated with monitoring
for the appearance of specific cell types during the early stages
of differentiation in culture. Identification of target cells can bedif-
ficultwhenchanges ingeneexpressiondonotmanifest visually or
when thedesiredmorphology isnot easily recognized. Traditional
methods have relied on relatively time-consuming immunological
analysis (e.g., fluorescence-activated cell sorting [FACS] and im-
munohistochemistry) and the reverse transcriptase polymerase
chain reaction (RT-PCR) to detect expression of specific marker
genes (Cai et al., 2007;Shimet al., 2007;Wanget al., 2005). These
tests often result in a significant loss of viable cells. FACS can be
used to purify viable differentiated cell types, but only if a specific
marker is expressed on the cell surface and if a suitable antibody
exists for its detection. In the context of transplantation, it is es-
sential to be able to purify cell types of interest because grafting
of undifferentiated cells could result in the formation of teratomas
(Brustle et al., 1997; Deacon et al., 1998; Hentze et al., 2006).
Genetic modification of ESCs may be undertaken to efficiently
derive pure populations of specific cell types. Efforts to optimize
differentiation protocols will be aided by the introduction of fluo-
rescent reporter genes to mark specific ESC derivatives, by
permitting rapid screening of live cells over a wide range of condi-
tions. The efficiency of these protocols may be further enhanced
byectopic expressionor silencing of specific genes. In this review,
we outline some of the genetic approaches that have been suc-
cessfully applied tohESCsanddiscuss their strengths, limitations,
and prospects in the context of generating specific derivatives. As
the geneticmanipulation of hESCs is relatively new, several exam-
ples presented in this review have been conducted with murine
ESCs (mESCs). In those cases, it is expected, but not yet deter-
mined, that similar outcomes can be achieved with human cells.422 Cell Stem Cell 2, May 2008 ª2008 Elsevier Inc.Identification and Purification of Specific ESC
Derivatives Using Stably Integrated Fluorescent
Reporter Genes
The Power of Fluorescent Reporters
Cell-specific promoter-driven expression of antibiotic resis-
tance markers followed by appropriate drug selection has been
used to purify specific ESC derivatives. Indeed, some of these
cells have proven effective in grafting experiments and in the
treatment of mouse models of human disease (Anderson
et al., 2007; Klug et al., 1996; Li et al., 1998; Soria et al., 2000;
Wang et al., 2007a). However, it is difficult to monitor the kinet-
ics of marker gene expression in these systems, which detracts
from their usefulness during optimization protocols. Drug-
selectable markers are also undesirable if their expression per-
sists once the population of interest has been purified and
transplanted.
In contrast, the introduction of fluorescent reporter genes un-
der the control of cell type-specific promoters offers several
advantages and is considered the best method available to
identify and enrich for particular progenitor or specialized cell
types. Fluorescent reporters are generally preferred over gene
tags such as b-galactosidase and human placental alkaline
phosphatase, as they can be detected in culture by fluores-
cence microscopy without requiring fixation or exposure to
chromogenic substrates (Hadjantonakis and Nagy, 2001). In
addition, cells expressing fluorescent markers can be easily pu-
rified by FACS. These foreign markers can also be used to
track transplanted cells in vivo, by analysis of individual organs
and tissues, and possibly in live animals by noninvasive whole-
body imaging, as has been performed to investigate green fluo-
rescent protein (GFP) expressing tumors in mice (Hoffman,
2004). Most reports of fluorescent gene markers have utilized
the autofluorescent proteins GFP and EGFP (enhanced GFP).
Many others are now available, including ECFP (where C is
cyan), EYFP (where Y is yellow), and specific DsRed mutants
(e.g., monomeric versions with reduced tendency to aggregate
in vivo), and their safety and applicability in vivo have been
demonstrated (Hadjantonakis et al., 2002; Long et al., 2005;
Vintersten et al., 2004).
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Currently, there exist three approaches to generating an ESC re-
porter line. They are described in detail under the subheadings
below. Unless otherwise indicated, each employs the use of
a constitutively expressed positive selection marker, typically
one which confers antibiotic resistance, to identify clones that
have incorporated the construct. Genetic selection strategies
have, however, proven difficult with hESCs due to their poor sur-
vival at low density and as single cells, and these often result in
low cloning efficiency. This challenge may be overcome by in-
cluding neurotrophins in the culture medium (Pyle et al., 2006).
hESCs express tropomyosin-related kinase (TRK) family recep-
tors that are responsive to brain-derived neurotrophic factor
(BDNF), neurotrophin 3 (NT3), and neurotrophin 4 (NT4). The
presence of these neurotrophins in culture medium increased
clonal survival through antiapoptotic effects and stabilized chro-
mosome ploidy after high-throughput passaging. Indeed, the
presence of these factors significantly improved the stable trans-
fection efficiency mediated by nucleofection (Hohenstein et al.,
2008). A selective inhibitor of p160-Rho-associated coiled-coil
kinase (ROCK) inhibitor, the Y-27632 compound, was also re-
ported to increase survival of dissociated hESCs by reducing
apoptosis, thus promoting clonogenicity (Watanabe et al.,
2007). In addition, it improved the subcloning efficiency after
stable integration of selection markers. Y-27632 was also found
to be highly effective in maintaining survival when dissociated
hESCs were subjected to stressful conditions in serum-free sus-
pension culture. This is in contrast to BDNF, NT3, and NT4,
which demonstrated weak effects in similar conditions. A com-
parison of both treatment strategies under identical culture con-
ditions has not been reported.
Once transgenic or correctly targeted (and karyotypically nor-
mal) clones have been obtained, it is desirable to remove the
positive selection marker to prevent potential competition with
the reporter gene promoter for access to transcription factors.
This can be accomplished with the bacteriophage P1-derived
loxP-Cre or the Saccharomyces cerevisiae-derived FRT-Flp re-
combination systems (Branda and Dymecki, 2004). Recently,
site-specific recombination of almost 100% efficiency was dem-
onstrated in hESCs harboring a stably integrated loxP-flanked
construct that were transduced with recombinant-modified Cre
recombinase protein (Nolden et al., 2006). A TAT peptide was in-
troduced at the N terminus of the protein to allow efficient uptake
by the cell, in addition to a nuclear localization signal (NLS). This
method is rapid and efficient when compared with the conven-
tional approach, which uses transient transfection of a Cre
recombinase expression vector, and removes the possibility of
genetic uptake by the target cells.
Transgenic Approach: Random Integration
of a Promoter-Driven Reporter Gene
DNA Delivery Methods. As mentioned above, there are currently
three categories of approaches used to genetically modify ESCs
to mark these cells or their derivatives. The first method involves
the randomgenomic integration of a construct that uses a cell- or
tissue-specific promoter fragment to drive reporter gene expres-
sion. Transgenes can be introduced into the ESC genome by
plasmid transfection using electroporation, nucleofection, or
chemical-based transfection reagents, or viral-mediated transfer
might also be used. For viral transduction, lentiviruses arepreferred due to their relative stability, as they are less prone to
silencing and because they offer the greatest efficiency of all cur-
rent delivery methods (Menendez et al., 2005; Siemen et al.,
2005; Zeng et al., 2007). To date, only a few published reports
have made direct comparisons between the various DNA deliv-
ery methods used to modify hESCs. For example, nucleofection
was found to be more efficient in mediating plasmid transfection
compared with electroporation and lipofection (Lakshmipathy
et al., 2004; Siemen et al., 2005). The chemical reagents FuGENE
6, Lipofectamine 2000 (both of which are lipid based), and ExGen
500 (cationic-polymer based) have also been compared, and
two studies indicated that the latter approach was less effective
(Siemen et al., 2005; Vallier et al., 2004b), in contrast with the re-
sults of another report (Eiges et al., 2001). A more recent report
that compared a wide range of chemical transfection reagents
corroborated the relatively poor efficiency of ExGen 500 and
identified GeneJammer to be superior to all methods tested
(Anderson et al., 2007). It remains possible that the performance
of specific reagents may vary according to the culture system
and/or the cell line used. At present, it is recommended that
individual laboratories test multiple reagents to determine the
most effective transfection method for their specific purpose.
hESC Transgenic Successes to Date. Transgenic technology
has been used to monitor the differentiation status of hESCs
with EGFP driven by the hESC-specific OCT4 (also known as
POU5F1) promoter fragment (3917 to +55, relative to the tran-
scription start site) (Gerrard et al., 2005). Use of the OCT4 pro-
moter fragment distinguished undifferentiated hESCs from their
differentiated progeny based on their green fluorescence. Simi-
larly, a murine Rex1 promoter fragment was used earlier for the
same purpose, representing the first report of the isolation of
genetically modified hESCs (Eiges et al., 2001). Transgenic re-
porters have also been utilized to tag specific hESC derivatives.
Motor neurons can be derived from hESCs after in vitro culture in
the presence of sonic hedgehog and retinoic acid. Differentiated
cells from these cultures were identified based on GFP expres-
sion regulated by the 50 enhancer region of the transcription fac-
tor Hb9, and isolated cells displayed functional neuronal traits
in vitro (SinghRoy et al., 2005). In another example,EGFP expres-
sion controlled by a 560 bp human myosin light chain-2V pro-
moter fragment was used successfully to mark cardiomyocytes
generated in a human embryoid body (EB) differentiation system
(Huber et al., 2007). These cells demonstrated long-term engraft-
ment in rat hearts. Fluorescent reporter transgenes using murine
albumin (410 bp) and Pdx1 (4.5 kb) promoter fragments were
also used to identify hESCs differentiating toward the hepatic
and pancreatic lineages, respectively (Lavon et al., 2004, 2006).
Limitations and Caveats. An important shortcoming of the
transgenic labeling approach is exemplified by a study that
used a 4.5 kb BglII fragment containing the MYH6 promoter
(Anderson et al., 2007). In this example, the promoter was used
to regulate coexpression of GFP and puromycin-N-acetyltrans-
ferase through the use of an internal ribosome entry site (IRES),
in order to facilitate identification and enrichment of cardiomyo-
cytes derived from hESCs. Despite detection of the GFP tran-
script in resulting cardiomyocytes, no fluorescence signal was
observed. However, the cells were resistant to puromycin,
suggesting that this promoter was not strong enough to produce
observable levels of GFP protein, whereas the resistance geneCell Stem Cell 2, May 2008 ª2008 Elsevier Inc. 423
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sociated with the use of fluorescent reporter genes for marking
lineages. Where sufficient information is available, strong, spe-
cific promoters should be selected. Alternatively, the potency
of the candidate construct should be tested in a cell line known
to express the endogenous gene, as done by Lavon et al. (2006),
to help determine its suitability in lineage specification studies.
An additional point to consider in designing a transgenic re-
porter line is that promoter fragmentsmay not always harbor suf-
ficient information to direct faithful expression of the reporter, in
that other elements of upstream or downstream sequences may
also be required. In addition, insertion position can have strong
effects on transgene expression. Genes integrated in highly
compact regions of the genome are likely to be silenced or dem-
onstrate reduced levels of expression due to poor accessibility
by transcription factors (Burke andBaniahmad, 2000). The trans-
gene may also disrupt another gene that could affect the pheno-
type of the cells. Due to these potential position effects, there is
a recognized need to generate and analyze several transgenic
lines. Site-specific integration issues may be more of a problem
when using lentiviruses, as there is often more than one integra-
tion site in a single transduced cell (Hamaguchi et al., 2000). High
viral loads used to transduce hESCs with an EGFP transgene
were correlated with a reduced ability to differentiate, probably
due to an increased level of DNA damage (Clements et al.,
2006). This problem, however, can be diminished by titrating
the virus particles prior to infecting the cells to determine the op-
timal infecting dose. Clonal variation in transgene expression, si-
lencing, and random gene disruption may be circumvented by
using recombinase-mediated cassette exchange (RMCE; dis-
cussed below) to introduce the transgene into a genetically mod-
ified, transcriptionally active site, such as the ROSA26 locus in
the HES2.R26 line (Irion et al., 2007). Alternatively, the phiC31 in-
tegrase system (Thyagarajan et al., 2008) may also find utility,
and this is discussed in more detail in a subsequent section.
The knockin approach resolves each of these problems and
also enables more precise gene-specific expression.
Knockin Approach: Targeted Integration
of the Reporter Gene
Reporter knockins involve the insertion of a marker gene into
a specific site within a gene of interest by homologous recombi-
nation. This targeted approach enables the reporter to be ex-
pressed according to the regulatory mechanisms controlling ex-
pression of the endogenous gene. Although it is much more
difficult to achieve knockins compared with the promoter-driven
approach, the reporter will be subjected to the same epigenetic
conditions and chromosomal environment (e.g., methylation,
acetylation, and histone structure) as the endogenous gene
and is therefore more likely to faithfully reflect the activity of the
target promoter.
Targeting Strategy and Vector Considerations. In most cases,
it is easiest to introduce the reporter at the 50 end of the coding
sequence so that it uses its own translation start site or that
of the native gene. If the reporter is introduced within the coding
sequence, it is essential that it is in frame with the endogenous
gene. In either case, targeting will often result in the disruption
of transcription or translation of the endogenous gene. However,
this deficiency may not pose a problem for all knockins, as in
many cases one wild-type allele is sufficient to maintain a normal424 Cell Stem Cell 2, May 2008 ª2008 Elsevier Inc.phenotype. Alternatively, the reporter could be cloned at the
30 end of the gene, downstream from the sequence encoding
the stop codon. In this situation, an IRES may be utilized to allow
two different protein products to be derived from the same tran-
script. It is important to note, however, that protein expression of
the second gene has been shown to be less efficient than the first
gene, to variable degrees (Mizuguchi et al., 2000), and that
mRNA stability can be affected and result in aberrant expression
of the endogenous gene (Miquerol et al., 2000). For example, in-
sertion of an IRES-lacZ-SV40pA cassette into the 30 untranslated
region of the Vegf-A gene slightly elevated Vegf-A mRNA and
protein levels and resulted in embryonic lethality of homozy-
gotes. The IRES has also been found to function poorly in hESCs
(Hasegawa et al., 2007). An alternative strategy to enable effi-
cient multicistronic transgene expression in hESCs may be
through the use of the foot-and-mouth disease virus (FMDV)
2A segment (Hasegawa et al., 2007). However, protein products
of both the endogenous gene and transgene may be compro-
mised due to the addition of several amino acids to the C termi-
nus of the first protein and the addition of an amino acid to the
N terminus of the second protein.
A gene-targeting construct consists of 50 and 30 homology
arms flanking a promoterless reporter gene to precisely target
the desired modification and also carries a positive selection
marker, such as the neomycin phosphotransferase (neo) gene.
Correctly targeted clones are identified after antibiotic selection,
PCR, andSouthernblot analysis.Clonesharboringa randomly in-
tegrated construct can be eliminated by including a negative se-
lection marker in the bacterial vector backbone of the targeting
construct. A typical example is the HSV-tk gene, the expression
of which results in the elimination of cells in the presence of gan-
cyclovir. Recently, a modification of the positive-negative selec-
tion strategy (Mansour et al., 1988) hasbeendeveloped inmouse,
wherebydrug resistancegenes havebeen replacedwith different
fluorescent reporters (Hatada et al., 2005). As fluorescentmarker
expression can be detected earlier, and separation of individual
putative homologous recombinants can be performed by
FACS, this method offers a more efficient and less laborious se-
lectionprocessover growing andanalyzing individual colonies. In
light of recent reports demonstrating clonal growth of single
hESCs, it is likely that thismethodwill alsobeapplicable tohESCs
(Davis et al., 2007; Irion et al., 2007; Nicholas et al., 2007).
To date, of the six detailed reports that perform gene targeting
in hESCs (HPRT and OCT4 each with two different constructs,
ROSA26, and MIXL1), and a brief report demonstrating specific
targeting of three different loci in one or more hESC lines, the
combined length of the homology arms ranged from 5.1 to
12.8 kb (Costa et al., 2007; Davis et al., 2007; Irion et al., 2007;
Urbach et al., 2004; Zwaka and Thomson, 2003). Of the seven
cases in which the information is readily available, the size of
the short arm ranged from 1.6 to 6.3 kb, and the long arm ranged
from 5.3 to 12.8 kb. One study investigated the impact of in-
creasing the size of one of the homology arms (Zwaka and
Thomson, 2003). As documented in studieswithmESCs, a signif-
icant increase in homologous recombination was observed with
the larger construct, i.e., 40% of the G418-resistant clones
obtained (6.5 kb 30 arm) were targeted compared with a
27% targeting efficiency obtained with the smaller construct
(1.6 kb 30 arm).
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used method for gene targeting experiments in mESCs, and it
was found to be more efficient when compared with lipofection
in a range of human cell lines (Yanez and Porter, 1999). The
few initial studies with hESCs indicated that it has been difficult
to achieve stable DNA delivery into hESCs by electroporation.
In contrast, a recent, brief report from the Stanley laboratory
(Costa et al., 2007) describes a new electroporation protocol
that led to successful, robust gene targeting of three different
loci in one to four different hESC lines. There have also been
five detailed reports on gene targeting in hESCs, four of which
were knockins, which utilized electroporation (Davis et al., 2007;
Irion et al., 2007; Urbach et al., 2004; Zwaka and Thomson,
2003). Only one report exists, to date, in which homologous
recombination was achieved successfully via chemical transfec-
tion of hESCs (Urbach et al., 2004). The recently developed elec-
troporation-based technique nucleofection may be preferred in
the future, as it appears to be more efficient at introducing plas-
mid DNA into both mouse and human ESCs and has facilitated
generation of stably transfected clones (Hohenstein et al.,
2008; Lakshmipathy et al., 2004; Siemen et al., 2005).
hESC Knockin Proof-of-Principle Successes to Date. Modifi-
cation of standard mESC electroporation protocols to suit the
different characteristics of hESCs enabled two different genes,
HPRT (hypoxanthine phosphoribosyltransferase-1) and OCT4,
to be targeted in hESCs (Zwaka and Thomson, 2003). The chem-
ical methods tested failed to yield homologous recombinants. A
rapid result was obtained by knocking out theHPRT gene. This is
possible because, in addition to the traditional positive-negative
selection (Mansour et al., 1988), the gene is X linked and so se-
lection of colonies lacking the functional protein product is pos-
sible with 2-amino-6-captopurine (6-TG). Hence, screening nu-
merous colonies by molecular methods is avoided. A knockout
at the human HPRT locus has also been achieved with ExGen
500 and a nonisogenic DNA construct (Urbach et al., 2004). An
EGFP knockin was created by using a promoter trap approach
at the OCT4 genomic locus with two constructs differing in the
size of the 30 homology arm (Zwaka and Thomson, 2003). IRESs
were used to generate a fusion transcript containing the OCT4,
EGFP, and neo coding sequences from which all three protein
products were derived. Hence, correctly targeted ESC clones
were easily identified and enriched by their ability to fluoresce
in combination with their resistance to G418. Homologous re-
combination was also used to insert the tandem-dimer red fluo-
rescent protein tdRFP cDNA into the ROSA26 locus (Irion et al.,
2007). Again, a promoter trap approach was used whereby neo
expression was activated in hESCs upon proper insertion at the
ROSA26 locus and subsequently used to select targeted clones.
The neo cassette was followed by an inverted tdRFP cDNA. loxP
and loxP2272 sites were included and specifically arranged to
enable excision of the neo cassette with inversion of the tdRFP
cDNA upon exposure to Cre recombinase, allowing the reporter
gene to be regulated by the ROSA26 promoter. These cell lines
are valuable and can be of general utility to the hESC community.
The targeted lines, prior to Cre-mediated excision of the neo cas-
sette, can be used in combination with Cre transgenes controlled
by various cell- or tissue-specific promoters for lineage-tracing
studies. As mentioned earlier, the Cre-modified lines can be
used to insert sequences of interest into the ROSA26 site viaRMCE. The generation of an hESC reporter knockin line to
mark specific derivatives has only recently been reported (Davis
et al., 2007). In this case, theGFP cDNA was inserted into the lo-
cus ofMIXL1, a gene that is transiently expressed in the primitive
streak during embryogenesis. The correlation between GFP and
MIXL1 expression was investigated in a spin EB system, using
BMP4 or Activin A to induce their expression. GFP transcription
mirrored that of endogenousMIXL1, demonstrating coordinated
gene expression consistent with embryogenesis, i.e., initial
switching off of stem cell markers and transient coexpression
with primitive streak markers, followed by activation of endoder-
mal andmesodermal markers. A strong correlation was detected
between fluorescence and MIXL1 protein expression, in that
83.3% ± 7.7% (n = 4) of GFP+ sorted cells stained with MIXL1
antibodies. MIXL1 expression was almost absent from the
GFP fraction. It was noted that GFP fluorescence persisted be-
yond detection of MIXL1 expression, a phenomenon attributed
to the longer half-life of the GFP protein, which is still useful for
lineage tracing. GFP fluorescence, together with expression of
the cell surface marker PDGFRa, enabled FACS-based enrich-
ment of a population of primitive hematopoietic precursors.
This study represents the first gene-targeting experiment in
hESCs that, unlike previous reports, does not rely on a promoter
trap method to enable selection of targeted hESCs (Irion et al.,
2007; Zwaka and Thomson, 2003) or drug resistance resulting
from gene disruption (Urbach et al., 2004; Zwaka and Thomson,
2003). Hence, it can be applied to target genes that are
not expressed in hESCs and provides a method to identify
targeted gene disruptions that do not result in a drug selectable
phenotype.
Zinc Finger Nucleases to Enhance Gene Targeting. The use
of zinc finger nucleases (ZFNs) and related enzymes (Pingoud
and Silva, 2007; Wu et al., 2007) represent novel modifications
to the gene targeting approach, making it more efficient by sev-
eral orders of magnitude. These nucleases are tailored to recog-
nize specific DNA sequences and induce a double-stranded (ds)
break within or adjacent to a chromosomal target site, resulting
in an enhanced rate of homologous recombination with exoge-
nous homologous DNA. ZFNs are composed of a nonspecific
FokI cleavage domain fused to a zinc finger protein (ZFP) that
typically contains a combination of three to four zinc finger mo-
tifs. Each motif recognizes a specific nucleotide triplet, and if
not for the lack of a targeting motif for every possible triplet, it
would be possible to design ZFNs for any DNA sequence. How-
ever, given that the ds break can be induced several hundred
base pairs away from the target site, the lack of some potential
targeting motifs is not a major impediment for application of
this technology. ZFNs function as dimers, and so one ZFN
matching each DNA strand is required for the reaction. ZFN-me-
diated gene targeting has been achieved in a variety of cell types,
including hESCs (Lombardo et al., 2007; Ptaszek and Cowan,
2007; Wu et al., 2007), since their original description just over
a decade ago. In the hESC study, a PGK-GFP cassette was tar-
geted to the CCR5 gene, using an integrase-defective lentiviral
vector (IDLV)-based targeting construct in HUES-3 or HUES-1
hESCs (Lombardo et al., 2007). When the cells were infected
with two additional IDLVs modified to express a pair of ZFNs
specific for a site in theCCR5 gene, the generation of GFP+ cells
was more efficient than when the GFP donor-IDLV wasCell Stem Cell 2, May 2008 ª2008 Elsevier Inc. 425
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theGFP transgene in the former, but not the latter. This particular
hESC study lacked Southern blot analysis, which would have re-
vealedwhether proper targeting hadbeen achieved to yield a sin-
gle-copyGFP insertion andwhether any random integrants were
generated. Indeed, it is important to note that combined South-
ern blot and PCR analysis revealed that K-562 cells treated with
the same vectors gave rise to multiple GFP+ clones that carried
variable GFP copies and vector sequences at the desired inte-
gration site, in addition to the intended single GFP copy integra-
tion. In addition to verifying proper targeting when using ZFNs, it
is important that exposure to the nuclease-expressing vectors
be limited, and transient, because continuous expression of
ZFNs appears to be detrimental to cells, believed to be a conse-
quence of off-target site cleavage (Wu et al., 2007). IDLV vectors
seem suited for this task, given that protein derived from an
IDLV-delivered GFP transgene was detected only transiently in
infected HEK293 cells and cord blood CD34+ progenitor and
stem cells (Lombardo et al., 2007). However, loss of the vector
was not confirmed at the DNA level, leaving open the possibility
that lingering ZFN homodimers and monomers might induce
nonspecific cleavage and lead to mutations via nonhomologous
end-joining at the fused site (Wu et al., 2007). Overall, ZFN tech-
nology may find general utility in hESC targeting experiments in
the future; however, fine tuning of specificity and rapid, less
tedious methods for ZFN design, production, and validation
are required. As an initial step, improvements have been made
recently to prevent the formation of homodimers (Pingoud and
Silva, 2007).
Artificial Chromosome Approach: Random or Targeted
Integration of the Reporter Gene
Recently, mESCs have been transfected with bacterial artificial
chromosomes (BACs) carrying entire murine genes that have
been modified by insertion of a reporter gene. Upon differentia-
tion, the reporter genes demonstrated similar expression to the
endogenous gene (Tomishima et al., 2007; Wang et al., 2007b).
This system is currently applicable to a wide range of genes
because of the availability of a BAC GFP transcriptional fusion
library (GENSAT), comprising >400 different BACs that can be
easily modified (Tomishima et al., 2007). In addition, such con-
structs can be generated with relative ease by employing
BAC recombineering protocols (http://www.genebridges.com/)
(Valenzuela et al., 2003; Wang et al., 2007b; Yang and Seed,
2003). Indeed, these methods can also be applied to generate
conventional targeting constructs, but they use a slightly more
complex approach. Stable integration of recombinant BAC
DNA can be random or targeted (Valenzuela et al., 2003; Yang
and Seed, 2003), and the targeting efficiency observed with
BAC DNA in mESCs has been shown to be improved relative
to nonchromosomal vectors.
BAC-Associated Challenges. The use of targeting vectors that
harbor extensive homologous sequences has been avoided in
the past due to the challenges involved in using standard molec-
ular screening methods (PCR and Southern blotting) to identify
correctly targeted clones (Valenzuela et al., 2003). Size restric-
tions apply to PCR-amplifiable fragments, making it difficult, if
not impossible, to amplify the region that spans the modification
and sequences external to one of the homology arms when very
large vectors are used. For Southern blotting, one restriction site426 Cell Stem Cell 2, May 2008 ª2008 Elsevier Inc.must be situated external to one of the arms, and the other site
situated either within the modified region or within or external
to the other arm. The larger the homology arm, the harder it be-
comes to identify suitable restriction enzymes. In addition, it can
be very difficult to resolve wild-type and targeted bands when
the probes used contain sequences common to both fragments.
A novel approach was used in the Yang and Seed (2003) study,
whereby PCR was used after positive selection to eliminate ran-
dom integrants by amplification of vector sequences flanking the
genomic DNA insert (since the entire BAC linearized in the vector
backbone was introduced). Then, the BAC was used as a probe
to analyze putative targeted clones by chromosomal fluores-
cence in situ hybridization (FISH). Clones producing more sig-
nals than the wild-type mESCs represented random integrants,
whereas those which produced signals identical to the wild-
type cells were considered putative targeted clones. Further
characterization by Southern blot indicated that no rearrange-
ments had occurred within the construct derived sequences;
however, this method could not distinguish between random
and targeted events. To screen for targeted clones among
drug-selected colonies, Valenzuela et al. (2003) employed a var-
iation of the real-time PCR protocol to assay for the loss of one
allele. Chromosomal FISH analysis using the BAC and reporter
gene as probes confirmed the results obtained from the ‘‘loss-
of-native-allele’’ assay in all 61 clones investigated. This screen-
ing approach, although clever and useful for deletion targeting
approaches, will not be effective for situations in which inser-
tional targeting is employed. Insertional strategies are preferred
when reporter genes are sought to mark endogenous locus ac-
tivity, because sequence deletion may impact on gene regula-
tion. In addition, the success of this PCR-based screening
method depends on the size of the deletion and knowledge of
the sequences that are lost. In summary, recombinant BAC con-
structs offer the potential to achieve more rapid knockin gene
targeting, due to the relative ease of obtaining and modifying
BACs, and increased targeting efficiency, due to higher homol-
ogy. However, a risk of simultaneous random integration of
a small fragment(s) derived from the BAC remains, as large
DNA molecules are susceptible to shearing. This is not an insig-
nificant issue, given the challenge associated with screening for
such occurrences, as they may be too small to detect via FISH
screening methods.
In addition to their use as targeting vectors, BAC-delivered
modifications can also be randomly integrated. In this case,
the inclusion of extensive genomic sequences (up to 350 kb) im-
proves the likelihood that the reporter gene will be subject to the
same regulatory conditions (DNA elements and chromatin struc-
ture) associated with the endogenous locus. This advantageous
feature of BAC-based delivery is shared with knockins, but not
promoter-driven, randomly integrated transgenics. However,
analysis of a number of clones is still advised to ensure that po-
sition effects do not arise. One advantage of nontargeted BAC
usage over knockins is that both functional copies of the endog-
enous gene of interest remain intact. This feature offers a distinct
benefit in situations where haploinsufficiency is an issue. The
obvious pitfalls of this system, however, are gene disruption
due to random integration and potential ectopic expression of
other genes present in the BAC. Regardless, this method has
yet to be demonstrated for hESCs.
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Promote Differentiation toward a Specific Fate(s)
Genetic modifications are not only useful tools to track hESC de-
rivatives, but they can also be performed in order to induce dif-
ferentiation into desired cell types. In this approach, rather
than relying on culture conditions and stochastic events, ectopic
expression or suppression of a key developmental gene(s) can
be induced in the ESCs themselves to direct differentiation to-
ward specific phenotypes of interest. However, differentiation
usually requires the temporal expression of specific combina-
tions of genes, and therefore the early and/or persistent expres-
sion or downregulation of a certain gene(s) may affect the cells’
ability to become more specialized. Overexpression of certain
gene products can also be toxic to cells. Therefore, controlled
removal or modulation of genetic modifications affecting gene
expression must be feasible. Inducible systems such as loxP-
Cre/FRT-Flp recombination or tetracycline (tet)-regulated (TET-
ON/TET-OFF) systems can be incorporated to control ectopic
gene expression and silencing (Branda and Dymecki, 2004;
Sprengel and Hasan, 2007).
Ectopic Expression of a Transgene(s)
Expression Vector Delivery and Considerations. Methods to in-
troduce transgenes into hESCs were discussed in a previous
section. Random integration of transgenes to rapidly identify
the effects of ectopic gene expression is acceptable in in vitro re-
search settings. However, as discussed, issues such as clonal
variation in transgene expression or silencing due to position ef-
fects and potential random gene disruption necessitate that mul-
tiple cell lines are examined to derive meaningful conclusions.
Random integration is generally not an issue for adenoviruses
and baculoviruses, both of which have been shown to be capa-
ble of transducing hESCs (Smith-Arica et al., 2003; Zeng et al.,
2007), as they mainly exist as episomes in the host cell. These vi-
ruses may find some utility in directed differentiation protocols
where transient protein expression is preferred, as loss of the
episome occurs during cell division. Provided that protein ex-
pression does not require tight regulation, this approach could
be useful. However, use of viral vectors in a therapeutic context
may be precluded due to potential immunogenicity (Bangari and
Mittal, 2006), unless complete loss of the viral genome is demon-
strated prior to transplantation.
The limitations of randomly integrated transgenes can be cir-
cumvented by using homologous recombination to target the
transgenes to specific genomic sites that are transcriptionally
active in all cell types and that exhibit no functional conse-
quences when one copy is disrupted. The ROSA26 locus is
a well-known example of such a site (Friedrich and Soriano,
1991; Irion et al., 2007; Zambrowicz et al., 1997), and the
ENVY locus appears to demonstrate similar features (Costa
et al., 2005). Use of such sites may allow the overexpression of
specific lineage-inducing genes or the knockdown of gene ex-
pression via an RNAi approach (see below). An hESC line has
been reported in which the tdRFP inserted into the ROSA26 lo-
cus is flanked by heterotypic loxP sites (Irion et al., 2007). This
cell line thus provides a ready resource for targeting exogenous
sequences with RMCE, by transient cotransfection of an ex-
change vector harboring the DNA of interest flanked by hetero-
typic loxP sites and a Cre recombinase expression vector.
Replacement of the tdRFP cDNA was demonstrated with twodifferent cDNAs in the absence of drug selection. If the exoge-
nous DNA is promoterless and contains an open reading frame,
it will be constitutively expressed, according to theROSA26 pro-
moter after RMCE. To achieve a more finely tuned expression,
transgenes containing their own promoters can also be intro-
duced.
Transgene targeting that avoids gene disruption can also be
achieved by using the phage-derived phiC31 integrase. Re-
cently, this integrase has been shown to mediate integration of
DNA plasmids containing native attB sites into pseudo-attP sites
present in the hESC genome (Ptaszek and Cowan, 2007; Thya-
garajan et al., 2008) that have been shown to lie within transcrip-
tionally active areas, at least in non-hESCs (Chalberg et al.,
2006). As a proof of principle, constructs harboring GFP driven
by either the cell-specific OCT4 promoter or the constitutive
EF1a promoter were separately cotransfected with a phiC31 in-
tegrase expression vector into hESCs (Thyagarajan et al., 2008).
After selection for stable integration of the GFP expression con-
structs, a significantly higher yield of stable clones was obtained
in the presence of the integrase. GFP-expressing hESC clones
were maintained in long-term culture. As expected, upon differ-
entiation, clones carrying the OCT4-GFP transgene lost their
fluorescent signal, whereas cells bearing the EF1a-GFP trans-
gene sustained their fluorescence, albeit at a slightly reduced
level. Plasmid rescue and sequence analysis identified some in-
tegration ‘‘hot spots,’’ and revealed that pseudo-attP sites are
mainly found within intronic or intergenic sequences. Using
these targeting sitesmay avoid undesired gene disruptions, con-
sistent with the lack of abnormalities detected in the transgenic
clones obtained. However, additional characterization of hot
spot transcriptional activity after differentiation is called for, as
well as studies to assess whether the sites lie within regulatory
and noncoding RNA sequences. A database containing informa-
tion on these hot spots has been proposed, and it will prove use-
ful for identifying suitable targeting sites and allow screening to
identify desired integrants. It is unclear why the hESC lines cho-
sen (BG01v and SA002) for the study were karyotypically abnor-
mal. Perhaps, the phiC31 integrase system will behave differ-
ently in karyotypically normal hESCs, and different hot spots
may be identified. This issue needs to be resolved.
Constitutive Transgene Expression to Induce hESC Differenti-
ation. There are many examples in the literature in which mESC
differentiation can be driven toward a particular fate by ectopic
expression of specific transcription factors (Blyszczuk et al.,
2003; Fujikura et al., 2002; Ishizaka et al., 2002; Kim et al.,
2002; Li et al., 2006; Zhao et al., 2004). Transgene expression
may indirectly promote differentiation by regulating the expres-
sion of numerous genes, in combination with other signals. For
example, HOXB4 overexpressing transgenic hESCs were main-
tained in an undifferentiated state as per wild-type cells, but
these demonstrated an increased propensity for hematopoietic
development upon in vitro differentiation (Bowles et al., 2006).
Directed differentiation may require more than one transgene
or the switching off of a transgene in some systems, given that
although EB culture of hESCs with a murine Pdx1 transgene
led to gene expression profiles consistent with pancreatic line-
age cells, insulin, a marker of pancreatic progenitors and b cells,
was not detected (Lavon et al., 2006). Indeed, enforced expres-
sion of multiple transcription factors (Oct3/4, Klf4, Sox2, andCell Stem Cell 2, May 2008 ª2008 Elsevier Inc. 427
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ation observed in reprogrammed murine somatic cells (Maherali
et al., 2007; Okita et al., 2007; Takahashi and Yamanaka, 2006;
Wernig et al., 2007). The resulting ESC-like induced pluripotent
stem (iPS) cells can contribute to high-percentage live chimeras
and/or generate teratomas in mice. The same factors and
a slightly different combination (OCT3/4, and SOX2, plus
NANOG and LIN28) can also reprogram human cells (Takahashi
et al., 2007; Yu et al., 2007). Subsequently, it was shown that
reprogramming is still possible, albeit even less efficient, when
c-Myc or LIN28 is omitted from the cocktail (Nakagawa et al.,
2008; Wernig et al., 2008). These examples clearly demonstrate
the ability of specific combinations and levels of ectopically ex-
pressed transcription factors to significantly alter a cell’s identity.
In addition to transcription factors, genetic modifications to
induce growth factor expression have been used to influence
cell-fate decisions in differentiating hESCs. In one example, con-
stitutive expression of Nodal induced visceral endoderm forma-
tion and preserved expression of pluripotency markers (Vallier
et al., 2004a).
Inducible Transgene Expression to Induce hESC Differentia-
tion. As discussed above, in many cases it is preferable to retain
temporal and cell-specific control over transgene expression.
Recently, a widely used conditional gene expression system
was integrated in hESCs to control the initiation of EGFP orNodal
transgene expression by administration of hydroxytamoxifen
(OHT) (Vallier et al., 2007). Stable cell lines with OHT-inducible
Cre recombinase activity were generated by constitutive expres-
sion of a Cre-ER2 fusion protein. Additional constructs using the
constitutively active CAGG promoter to drive expression of the
loxP-flanked b-galactosidase/Neomycin (bGeo) fusion protein
gene and the cDNA for either EGFP or Nodal was stably inte-
grated into the Cre-ER2 transgenic lines. The resulting cells
were resistant to G418 and demonstrated b-galactosidase
(b-gal) activity but did not exhibit significant EGFP orNodal trans-
gene expression. Addition of OHT to the culturemedium resulted
in Cre-ERT2-mediated recombination between the loxP sites to
excise the bGeo cassette, leading to loss of G418 resistance and
b-gal activity. Recombined cells demonstrated constitutive ex-
pression of EGFP or Nodal, with a maximal efficiency of 75%
EGFP-positive cells. InducedNodal expression resulted in a phe-
notype consistent with a previous report of ectopic expression of
this gene in hESCs (Vallier et al., 2004a). Use of Cre-ERT2 in
hESCs is limited by the observed toxicity of the active recombi-
nase in this population. Cell death can be minimized with careful
titration of dosage, duration, and time intervals betweenOHT ad-
ministration(s) and may also facilitate greater recombination effi-
ciencies. Another conditional gene regulation system employs
the TET-ON transactivator rtTA2SM2 and is both effective and
reversible in hESCs, unlike the Cre-based system (Vieyra and
Goodell, 2007). In this proof-of-principle study, a lentiviral-based
vector was used to generate stable cell lines constitutively ex-
pressing rtTA2SM2. These cell lines were then transduced with
another lentiviral vector containing the luciferase gene regulated
by a TET-ON responsive promoter. Addition of doxycycline (dox)
to the culture medium induced high-affinity binding of rtTA2SM2
to the TET-ON promoter and resulted in luciferase expression.
Clearly, this system offers a powerful tool to tightly regulate
transgene expression in hESCs and their derivatives.428 Cell Stem Cell 2, May 2008 ª2008 Elsevier Inc.Gene Silencing via the RNA Interference Approach
Differentiation can also be influenced by suppressing expression
of specific genes. Reduction of gene expression in hESCs is typ-
ically induced using lentiviral vectors for stable, high-efficiency
transduction of sequences encoding short hairpin RNAs
(shRNAs) due tomultiple insertions (Clements et al., 2006; Gropp
and Reubinoff, 2007; Rodriguez et al., 2007; Szulc et al., 2006;
Zaehres et al., 2005). Lentiviruses are advantageous in terms
of their ability to accept different promoters, are less prone to si-
lencing, and have a higher insert capacity compared with the
other popular stable viral delivery methods (Kobayashi et al.,
2005; Menendez et al., 2005; Suter et al., 2006). RNA interfer-
ence (RNAi) has also been achieved through plasmid transfec-
tion in hESCs (Liu et al., 2005). Given that some stem cell manip-
ulations will require the altered expression of multiple genes, it
was suggested that multiple transgenes should be delivered in
one lentiviral vector to reduce viral load. This strategy was
used to simultaneously express a reporter gene and silence an
endogenous gene (Clements et al., 2006). Recently, hybrid bacu-
loviral vectors have been developed containing sequences de-
rived from adeno-associated viruses, which can accept much
larger inserts than lentiviruses (%30 kb cf. a most effective size
of <10 kb); however, the stable transduction rates are much
lower (Park, 2007; Zeng et al., 2007). Transient downregulation
of genes in hESCs has been achieved with chemically synthe-
sized small interfering RNA (siRNA) (Hay et al., 2004; Hyslop
et al., 2005; Matin et al., 2004; Yamashita et al., 2006; Zou
et al., 2006). Where applicable, this approach may be preferred,
as thesemolecules do not integrate in the genome and thus have
only transient effects.
RNAi has been used to promote mESC differentiation toward
specific lineages in vitro, as determined by changes in morphol-
ogy and gene expression profiles (Ivanova et al., 2006; Yama-
shita et al., 2006; Zou et al., 2006). Hiraoka-Kaine et al. used
a TET-ON RNAi system to suppress Vegfr2 expression during
differentiation of mESCs to the mesoderm lineage in vitro
(Hiraoka-Kanie et al., 2006). Administration of VEGF to the cul-
ture medium at the mesoderm stage of differentiation normally
promotes formation of endothelial cells, but in the presence of
dox, virtually no cells of this lineage were detected. Few exam-
ples of shRNA-mediated downregulation of hESCs have been
reported to date, but biological effects of OCT4 and NANOG in-
terference have been observed (Hay et al., 2004; Hohenstein
et al., 2008; Hyslop et al., 2005; Matin et al., 2004; Rodriguez
et al., 2007; Zaehres et al., 2005). Suppression of these genes
induced differentiation of hESCs toward trophectoderm and
endoderm. Recently, the naturally occurring cardiac and skeletal
muscle-specific microRNAs (miRNAs) miR-1 and miR-133 have
been shown to influence lineage choice during differentiation of
mouse and human ESCs (Ivey et al., 2008). Lentivirus-mediated
overexpression of either miRNA promoted the formation of me-
soderm by elevating the levels of relevant markers and repres-
sing nonmuscle genes inmESCs. The twomiRNAs exhibited dis-
tinct effects at later stages of in vitro differentiation, with only
miR-1 leading to cardiac and skeletal progenitor production. In
differentiating hESCs, miR-1, but not miR-133, induced expres-
sion of the early cardiac marker NKX2.5 and also generated
3-fold more beating cardiac cells in vitro, compared to wild-
type cells. This finding is the first report to demonstrate
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numerousmiRNAs exist, eachwith the potential to downregulate
expression of multiple genes at the posttranscriptional level
(Zhao and Srivastava, 2007), RNAi-mediated differentiation of
ESCs will likely become more effective once the expression pro-
files of miRNAs in different lineages have been determined.
Concluding Remarks
Proof-of-concept experiments need to be performed in animal
models of human disease to test whether hESC derivatives are
functional and likely to be effective cell-based therapies for
humans. However, it is first necessary to be able to derive the
desired cell types in vitro. Genetic modification of hESCs is
expected to facilitate this process, specifically to mark cells of
desired lineages and also force differentiation toward specific
developmental pathways. Depending on the desired outcome,
different vector types and delivery methods will be more useful.
For example, for gene targeting applications such as the gener-
ation of reporter knockins, electroporation of plasmid DNA
currently appears to be most suitable. Similarly, due to its high
efficiency and effectiveness, lentiviral transduction is most
suited for gene silencing efforts—but not in a therapeutic setting.
Once pure differentiated populations have been obtained, they
must be characterized by extensive gene expression and/or
functional and morphological analysis to confirm identity. Many
genes are not truly lineage specific but are expressed in multiple
cell types; therefore, a thorough characterization is especially
important when the regulatory sequences of such genes are
used for tagging studies.
The knockin approach to generate fluorescent reporter lines is
preferred over the alternatives, mainly as it is able to provide a
consistent and more accurate readout of endogenous gene ex-
pression in the absence of random gene disruption. Refinement
of the ZFN technology couldmake gene targeting much easier to
achieve in the future. High-throughput methods tomodify hESCs
using the knockin approach will enable screening for factors
involved in differentiation and help optimize methods to derive
pure populations of specific cell lineages. By recapitulating the
temporal sequence of developmental gene expression patterns
during in vitro differentiation of hESCs, it is anticipated that the
progeny are more likely to be functional. Generation of dual or
multiple reporter knockin hESC lines should facilitate the
monitoring of gene expression during differentiation and the
identification of specialized cells as they arise. Once optimum
conditions have been established with knockin cell lines, these
lessons can be applied to direct differentiation of unmodified
hESCs lines in order to avoid the transfer of foreign gene expres-
sion markers in cell-based therapies.
Similarly, for therapeutic applications, it is preferred that any
ectopic gene expression or RNAi products used to drive in vitro
differentiation are removed prior to delivery to a patient, provided
that the resulting cells retain their desired phenotype. Deletion of
unwanted constructs can be accomplished with the loxP-Cre or
the FRT-Flp recombination systems; however, a byproduct of
their use is the persistence of a single loxP or FRT site at the inte-
gration site. By targeting the transgene to constitutively active
transcription sites that exhibit no phenotypic effects when disrup-
ted, any interference with the coding or regulatory sequences of
an endogenous gene can be avoided.An hESC line has beengen-430 Cell Stem Cell 2, May 2008 ª2008 Elsevier Inc.erated into which any DNA sequence of interest can be easily
inserted into the ROSA26 locus through RMCE. Alternatively,
the phiC31 integrasemaybeused to target such sites. In contrast,
the tendency of lentiviruses to integrate in multiple locations can
result in inter- and intrachromosomal recombination in the pres-
ence of Cre or Flp recombinase, producing major deletions, and
rearrangements at scattered recombination sites across the ge-
nome. For this reason, as well as their antigenicity, lentiviral vec-
tors should not be used for clinical purposes; however, their use
to address biological questions in vitro is encouraged. Effective,
high-yield generation of target cells will likely requiremanipulation
ofmultiple genes simultaneously and/or in sequence. Ideally,mul-
tiple transgenes and/or shRNAs should be delivered in one vector
together with regulatory systems, such as TET-ON, TET-OFF, or
Cre-ERT2, to allow for kinetic control of transgene expression.
In some situations, the limitations inherent to genomic modifi-
cations may be overcome by transducing hESCs with protein,
rather than genetic constructs, as demonstrated for Cre recom-
binase (Nolden et al., 2006). The addition of modified, recombi-
nant transcription factors to culture media may result in their
efficient uptake by the cells and, if followed by nuclear localiza-
tion, subsequently impact lineage choice. The ability to control
cell exposure to differentiation inducers is clearly important. In-
deed, TAT-mediated protein transduction has already been
demonstrated for the transcription factors Ngn3 and PDX1 in
mESCs and hESCs, respectively (Dominguez-Bendala et al.,
2005; Kwon et al., 2005). Addition of TAT-PDX1 to an EB culture
system resulted in increased mRNA expression of pancreatic
markers and the generation of insulin-producing cells. Protein
transduction technology can also be extended to Cre-ERT2
recombinase, phiC31 integrase, and ZFNs as they are only tran-
siently required, eliminating the dangers of DNA integration
inherent to most expression vectors.
Based on current accomplishments with hESCs and insights
from mESC studies, we have briefly described the genetic mod-
ification approaches that may be used to generate useful hESC
lines to serve as tools to enhance our ability to derive lineages
and cell types of interest for in vitro and therapeutic applications
(Table 1). We have identified the associated problems and chal-
lenges and proposed how they may be circumvented or best
addressed.
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